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Abstract 
The production of gelatinase B by macrophages is relevant in the immunological nd migratory functions of macrophages. CGP 
41251, an inhibitor of protein kinase C (PKC), was found to stimulate the expression of gelatinase B in macrophages, asshown by the 
study of two different monocytic/macrophagic cell lines, mouse RAW 264.7 and human THP-I cells. When human monocytes and rat 
peritoneal macrophages were treated with CGP 41251, insignificant increases of 10 and 25% were obtained. This can possibly be due to 
the presence of contaminating cells in these two enriched populations, since the CGP 41251 treatment of non-macrophagic cell lines 
inhibited their PMA-induced gelatinase B production• Taken together, these results suggest that the stimulatory effect of CGP 41251 is 
specific to cells of the monocytic lineage• Using RAW 264.7 cells as a model, the effect of CGP 41251 is additive to that obtained using 
lipopolysaccharide (LPS) and phorbol 12-myristate 13-acetate (PMA), as revealed by gelatin zymography and Northern blot analysis• The 
stimulatory effect of CGP 41251 on gelatinase B production in RAW 264.7 was: (a) inhibited by calphostin C (as is the LPS-induced 
response), indicating a PKC-dependence; (b) inhibited by dexamethasone (asopposed to the LPS-induced response); and (c) enhanced by 
addition of trans-retinoic acid (RA). In fact, RA can induce gelatinase B production, either alone or in synergy with LPS and/or CGP 
41251, since the combination of the three agents gives the highest gelatinase B response, at both the protein and the mRNA levels• This 
represents an important observation considering that RA is now being tested as an anti-cancer agent and proposed for prevention studies. 
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1. Introduction 
Abbreviations: ECM, extracellular matrices; FBS, fetal bovine serum; 
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RA, trans-retinoic acid. 
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Chronic inflammatory lesions, such as periodontitis, 
rheumatoid arthritis or interstitial nephritis, are infiltrated 
with large numbers of mononuclear leukocytes [1,2]. 
Among these cells, macrophages are now recognized as 
major effectors in the degradation and the turnover of 
extracellular matrices (ECM). Macrophages can regulate 
interstitial and synovial fibroblast functions through the 
secretion of several cytokines, particularly TNF-a and 
IL-1 [3]. Furthermore, macrophages can also be fine-tuned 
for controlled proteolysis of connective tissues through the 
release of matrix metalloproteinases (MMPs) and other 
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ECM-remodelling enzymes [4,5]. Recently, gelatinase B 
(MMP-9; EC 3.4.24.35), an enzyme known to cleave 
different ypes of collagen, gelatin and some other sub- 
strates (reviewed in Refs. [6-8]), received much attention. 
Gelatinase B is a 92 kDa enzyme secreted by a number of 
normal and transformed cells. Neutrophils [9], T-lympho- 
cytes [10,11] and monocytes/macrophages [4,12] were all 
reported to produce gelatinase B. In monocytes and in 
monocytic ell lines, constitutive levels of gelatinase B 
appear to be rather low; however, these levels are in- 
ducible, at both mRNA and protein levels, by agents uch 
as lipopolysaccharide (LPS), concanavalin A and phorbol 
12-myristate 13-acetate (PMA) [13,14]. This activation 
seems to follow a prostaglandin E2/cAMP-dependent 
pathway and can be down-regulated by IL-4 and interferon 
gamma [1,15]. Using U937, a human monocytic-like cell 
line, Saarialho-Kere et al. [16] reported that the induction 
of gelatinase B production by LPS occurs at a pretransla- 
tional level. Furthermore, it was suggested that gelatinase 
B production by U937 cells was regulated by a mechanism 
independent of the differentiation to macrophage-like c lls 
[17]. 
The murine RAW 264.7 cell line is a macrophage cell 
line originally established from the ascites of a tumor 
induced in a BAB/14 mouse by the intraperitoneal injec- 
tion of Abelson leukemia virus [18]. Numerous studies 
have utilized the RAW 264.7 cell line as a macrophage 
model, particularly for the study of LPS stimulation [19], 
either at the level of TNF-c~ [20] or nitric oxide [21]. This 
extensive use of RAW 264.7 has now established this cell 
line as a prototype for the study of macrophage functions. 
Using the RAW 264.7 cell line, our group recently ob- 
served contrasting effects of two protein kinase C (PKC) 
inhibitors, calphostin C and staurosporine, on both LPS- 
and PMA-induced gelatinase B production [22]. Calphostin 
C completely abolished gelatinase B production, whereas 
staurosporine enhanced it 3- to 4-fold. When tested alone, 
doses of staurosporine lower than 100 nM had no effect on 
gelatinase B production while doses higher than 100 nM 
were too toxic for the cells. We therefore used CGP 
41251, an analog of staurosporine previously shown to be 
less toxic [23], and studied PKC-dependent signaling path- 
ways for gelatinase B production by macrophages. In this 
paper, we are reporting that CGP 41251 stimulates ignifi- 
cant levels of gelatinase B in two different 
monocyte/macrophage cell lines, in a synergistic way, to 
the stimulation observed with LPS or PMA. Similar treat- 
ment of human blood monocytes and rat peritoneal 
macrophages only yielded insignificant increases of gelati- 
nase B production. CGP 41251 alone stimulates gelatinase 
B production in RAW 264.7 and THP-I cells. The CGP 
41251-induced gelatinase B production is inhibited by 
calphostin C and by dexamethasone, and appears to be 
calcium-independent. On the other hand, LPS- and CGP 
41251-induced gelatinase B production show a significant 
increase in the presence of trans-retinoic acid (RA), at 
both mRNA and protein levels. In fact, RA alone appears 
to be an inducer of gelatinase B production i  macrophages. 
2. Material and methods 
2.1. Reagents 
LPS (Escherichia coli, strain 0127:B8), gelatin (type A, 
from porcine skin), RA, A23187, dexamethasone and PMA 
were obtained from Sigma (St. Louis, MO, USA). Her- 
bimycin, okadaic acid, genistein and all tissue culture 
materials were obtained from Gibco-BRL (Grand Island, 
NY, USA). Calphostin C, KT 5720 and KT 5823 were 
purchased from Kamiya Biomedical Company (Thousand 
Oaks, CA, USA). Ethylenebis (oxyethylenenitrio) te- 
traacetic acid (EGTA) was obtained from Boehringer-Man- 
nheim (Laval, Quebec, Canada). CGP 41251 was gener- 
ously donated by Ciba-Geigy (Basel, Switzerland). 
2.2. Cell cultures and treatments 
All established cell lines were obtained from ATCC 
(American Type Culture Collection, Rockville, MD, USA) 
and were grown in culture media recommended by ATCC 
supplemented with 5% fetal bovine serum (FBS), 10 mM 
HEPES buffer and antibiotics (complete medium). Cells 
were scraped or trypsinized, seeded at a density of 2.5 × 
105 cells/ml in 24-well cluster plates, and incubated 18 h 
at 37oC (+5% CO2). Peripheral blood monocytes were 
isolated from human male volunteers, as previously de- 
scribed [4] and peritoneal exudate cells were collected 
from male Fischer F344/N rats (specific pathogen-free; no
inoculation) by repeated washing of the peritoneal cavity 
with ice-cold Hanks' balanced salt solution (HBSS). Hu- 
man blood monocytes and peritoneal macrophages were 
adjusted to 106 cells/ml in RPMI complete medium, 
seeded (1 ml/well) in 24-well cluster plates and further 
enriched by a 2-h adherence step at 37°C (+5% CO2). 
Monolayers were washed three times with warm medium 
to completely remove FBS. Fresh serum-free medium 
containing either LPS, CGP 41251 or RA at the specified 
concentrations were then added to the cultures. When 
inhibitors were used, cells were pretreated for 30 min at 
37oC (+5% CO 2) with varying doses of inhibitor before 
the addition of LPS or CGP 41251. Cells were further 
incubated for 18 h at 37oC (+5% CO2). Supernatants 
were harvested and stored at -20  o C until assayed. Cell 
monolayers were next fixed in formaldehyde (5% in PBS), 
washed with water and stained with crystal violet 1%. 
2.3. Detection of gelatinase B activity 
Gelatinase B activity of cell culture supernatants was 
determined by SDS/PAGE zymography using gelatin as a 
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substrate, as described by Masure et al. [9]. Briefly, aliquots 
of 20 /xl were run on 7.5% acrylamide gels containing 
0.1% gelatin for 18 h at 50 V, at room temperature. After 
electrophoresis, gels were washed to remove SDS, incu- 
bated 18 h at 37°C in a renaturing buffer (50 mM Tris, 5 
mM CaC12, 0.02% NaN 3, 1% Triton X-100). Subse- 
quently, gels were stained with Coomassie brilliant blue 
G-250 and de-stained in methanol/acetic a id. Gelatinase 
B was detected as unstained bands on a blue background. 
Gelatinase B activity was quantitated by computerized 
image analysis (BioRad, model GS-670 Densitometer, 
Mississauga, Ontario, Canada). Results are expressed as 
arbitrary scanning units. 
2.4. Determination of nitric oxide production 
NO production was determined by the evaluation of the 
nitrite concentration in culture supernatants, using the 
Griess reagent [24]. Briefly, 100 /~1 of culture supernatant 
was combined with 100 /xl of Griess reagent (1% sulfanil- 
amide /0 .1% naphthy le thy lene-d iam ine  
dihydrocloride/2.5% H3PO 4) and allowed to stand at 
room temperature for 10 min. Absorbance was measured at 
540 nm. Nitrite concentrations were determined using a 
standard curve obtained with NaNO 2. 
3. Results 
3.1. Effect of CGP 41251 on gelatinase B production by 
macrophages, monocytes and other cell lines 
Four different types of monocytes/macrophages w re 
treated for 24 h with a dose of 1 ~M of CGP 41251, both 
in the presence and in the absence of LPS (Fig. 1). For the 
THP-I cell line, PMA was used instead of LPS since 
undifferentiated THP-1 cells are unresponsive to LPS [13]. 
In two of the four macrophage cell types, RAW 264.7 and 
THP- 1, culture supematants from CGP 4125 l-treated cells 
showed a significant enhancement of the production of 
gelatinolytic activity when compared to untreated cells. In 
the case of human blood monocytes and rat peritoneal 
macrophages, densitometric analysis of the gels revealed 
insignificant increases of 10 and 25%, respectively. In all 
four macrophage cell types, the gelatinase band present in 
CGP 4125 l-treated samples co-migrated with that of LPS- 
or PMA-treated samples. In each case, the effect of CGP 
41251 was additive to that of LPS or PMA. CGP 41251 
was also tested with four non-macrophagic cell lines, 
whether in the presence or in the absence of PMA, as LPS 
has no effect on the gelatinase production of these cells 
(unpublished observations): all these cell lines produced 
constitutive levels of gelatinase A and three of them 
2.5. Northern blot analysis 
Cells were cultured in serum-free medium for 16 h prior 
to CGP 41251, LPS or RA stimulation, lysed with guani- 
dium isothiocyanate and total RNA was purified by cen- 
trifugation on CsC1 [25]. Aliquots of 15 /zg of RNA were 
size fractionated in a 1.1% agarose denaturing el contain- 
ing 5% formaldehyde and transferred onto a nylon mem- 
brane (Amersham Hybond-N, Oakville, Ontario, Canada). 
RNA were cross-linked by U.V. and the membrane prehy- 
bridized for at least 4 h in 50% formamide, 5 X Denhardt' s,
6 × SSC and 50 /xg/ml of sheered denatured salmon 
sperm DNA. Hybridization was performed in the same 
solution, to which 10% dextran sulfate and 2-5  × 106 
cpm/ml  of denatured probe were added. Murine gelatinase 
B (2.0 kb) cDNA was the Xbal/Aspl  fragment of the 
pSM2 plasmid [14]. The GAPDH (983 bp) probe was a 
reverse transcriptase (RT)-PCR product obtained with spe- 
cific amplifiers sets (Clontech, Palo Alto, CA, USA). 
Probes were labelled with 32p-dCTP (ICN Biomedical, 
Mississauga, Ontario, Canada) using the random primer 
labelling kit (Pharmacia LKB Biotechnology AB, Uppsala, 
Sweden). After 16 h, the membrane was washed twice (15 
min) with 2 × SSC, 0.1% SDS at 42°C and once (15 min) 
with 0.2 X SSC, 0.2% SDS at 60°C, then exposed with a 
Kodak X-Omat Ar (Eastman Kodak Company, Rochester, 
NY, USA) film at -70°C  with an intensifying screen. 
Densitometric analyses were obtained with a BioRad video 
densitometer (model GS-670). 
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Fig. 1. Effect of LPS and CGP 41251 on the gelatinase B production of
different ypes of monocytes/macrophages. Fourdifferent ypes of 
monocytes/macrophages (human blood monocytes (HBM), rat peritoneal 
macrophages (RPM), THP-1 ceils and RAW 264.7 cells), and four types 
of nonmacrophagic tumorigenic cells (MCF7, CaSki, HeLa and RL95-2) 
were incubated for 24 h at 37oC (+5% CO 2) in serum-free conditions. 
Cells were left untreated (1), or were treated with a stimulator (50 ng/ml 
of LPS for RAW 264.7 cells, HBM and RPM or 100 nM PMA for the 
other cell types (2), with 1 /zM CGP 41251 alone (3), or a mixed solution 
of LPS (or PMA)+ CGP 41251 (4). Supernatants were next collected and 
assayed for their gelatinase A and B production (indicated right) using 
gelatin zymography. Molecular weight markers appear on the left in 
kilodaltons. 
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Fig. 2. Dose-response effects of CGP 41251 on gelatinase B production, 
nitric oxide production and growth of RAW 264.7 cells. RAW 264.7 cells 
were treated for 24 h at 37oC (+5% CO 2) with different doses of CGP 
41251 in absence (filled bars) or in the presence of LPS (50 ng/ml) 
(empty bars). Supernatants were next collected and assayed for their 
gelatinase B production using gelatin zymography and densitometry (a), 
and for their NO~ concentration (b). Cell monolayers were also fixed 
with formaldehyde 5% and stained with crystal violet for evaluation of 
the toxic effect of the different reatments (c). The gelatinase production 
of LPS-induced cells and the stain content of unstimulated cells were 
arbitrarily evaluated as 100%. The results are expressed as the means+ 
standard error (S.E.) of three different experiments. 
(CaSki, HeLa and RL95-2) produced gelatinase B follow- 
ing PMA treatment. When tested alone, CGP 41251 had 
no significant effect on the production of both gelatinase A 
or B in any of these three cell lines (Fig. 1). In contrast to 
the observation with macrophages, CGP 41251 almost 
completely inhibited the PMA-induced production of 
gelatinase B in CaSki, HeLa and RL95-2 cells. Similar 
results were obtained with several other non-macrophagic 
cell lines, such as mouse B16.F1 melanoma nd human 
Hec 1B endometrial denocarcinoma (data not shown). 
3.2. CGP 41251-induced gelatinase B production in RAW 
264. 7 cells 
Mouse macrophage RAW 264.7 cells were treated for 
24 h with doses of CGP 41251 ranging from 31 nM to 250 
nM both in the presence or absence of an optimal dose of 
50 ng/ml of LPS [22]. Analysis of the zymograms showed 
that CGP 41251 alone (Fig. 2a) increased gelatinase B
production in a dose-dependent fashion. Moreover, the 
effect of CGP 41251 was synergistic with that of LPS. 
CGP 41251 alone had no effect on NO production of 
RAW 264.7 cells (Fig. 2b) and inhibited the LPS-induced 
NO response. When 250 nM CGP 41251 was used, a 53% 
decrease in the LPS-induced NO production was observed. 
A dose-response toxic effect was also observed when 
RAW 264.7 cell monolayers treated with CGP 41251 
alone were next stained with crystal violet (Fig. 2c). 
However, no significant oxic effect was observed when 
RAW 264.7 cells were treated with the CGP 41251/LPS 
combination. The dose of 250 nM of CGP 41251 was 
chosen for subsequent experiments. 
3.3. Modulation of gelatinase B production in RAW 264.7 
cells induced by LPS and CGP 41251 
In order to define the signal transduction pathways for 
gelatinase B secretion in macrophages several 
agonists/antagonists were tested. RAW 264.7 cells were 
treated for 30 min with 1 /zM calphostin C, 100 nM 
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Fig. 3. Effect of different agents on gelatinase B production of RAW 
264.7 cells. RAW 264.7 cells were left with no treatment (N) or treated 
for 30 rain at 37oC (+5% CO 2) with 1 /a,M calphostin C (C), 100 nM 
okadaic acid (O), 1 /zM herbimycin A (H), 50 ~M genistein (G), 1 mM 
EGTA (E), 1 mM A23187 (A), 1 /xM KT 5720 (K20), 1 /,tM KT 5823 
(K23), 100 nM retinoic acid (RA) or 10/xM dexamethasone (DX) before 
addition of medium alone (filled bars), LPS (50 ng/ml)  (hatched bars) or 
250 nM CGP 41251 (empty bars). All these agents were used at optimal 
doses, as determined in preliminary experiments (data not shown). Super- 
natants were next collected and assayed for their gelatinase production 
using gelatin zymography and densitometry. The gelatinase B production 
of LPS-induced cells was arbitrarily evaluated as 100%. In the group 
pretreated with agent and next treated with medium alone (filled bars), 
detectable l vels of gelatinase were observed only with RA pretreatment. 
The results are expressed as the means + S.E. of three different experi- 
ments. 
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okadaic acid, 1 /xM herbimycin A, 50 /zM genistein, 1 
mM EGTA, 1 mM A23187, 1 /~M KT 5720, 1 p~M KT 
5823, 1 /zM RA, or 10 /~M dexamethasone b fore the 
addition of LPS or CGP 41251. Only RA induced gelati- 
nase B production when tested alone (Fig. 3). Moreover, 
the effect of RA was additive to that of CGP 41251 and 
LPS. Calphostin C inhibited gelatinase B production in- 
duced by LPS and CGP 41251 by more than 80%. Okadaic 
acid, herbimycin A and genistein partially inhibited these 
responses (approx. 50%). EGTA, A23187, KT 5720 and 
KT 5823 had no significant effect. For EGTA pretreat- 
ment, the culture medium was changed 6 h after LPS 
addition in order to avoid the inhibitory effect of EGTA on 
gelatinase activity. Dexamethasone inhibited the CGP 
41251-induced gelatinase B production by 80% without 
affecting the LPS-induced response in a significant man- 
ner. None of the agents used had a significant toxic effect, 
except for calphostin C and genistein, which gave an 80% 
and a 50% decreased response, respectively. 
3.4. Dose-response effect of retinoic acid on gelatinase B
production in RAW 264.7 cells 
RAW 264.7 cells were treated for 20 h with doses of 
RA ranging from 10 -~2 to 10 -5 M, either in the presence 
or absence of LPS or CGP 41251. RA alone (Fig. 4) 
stimulated gelatinase B production of RAW 264.7 cells 
starting at 10 - l° M and reaching a plateau at 10 -7 M. 
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Fig. 4. Dose-response effect of trans-retinoic acid on gelatinase B 
production of LPS- and CGP 41251-induced RAW 264.7 cells. RAW 
264.7 cells were treated for 30 min at 37oC (+5% CO 2) with different 
doses of RA before addition of medium alone (filled triangles), LPS (50 
ng/ml)  (empty squares) or 250 nM CGP 41251 (filled squares). Super- 
natants were next collected and assayed for their gelatinase production, 
using gelatin zymography and densitometry. The gelatinase production of 
LPS-induced cells was arbitrarily evaluated as 100%. The gelatinase 
production of CGP 41251-induced cells represented 130% of the LPS-in- 
duced response (results not shown in the figure). The curves represent the 
means + S.E. of three different experiments. 
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Fig. 5. Effect of LPS, CGP 41251 and trans-retinoic acid on gelatinase B 
mRNA levels in RAW 264.7 cells. RAW 264.7 cells were treated for 18 
h at 37°C (+5% CO 2) with LPS (50 ng/ml),  250 nM CGP 41251 
and/or 100 nM RA. Total RNA was extracted and aliquots of 15 p,g 
were hybridized with 32 P-labelled probes specific for mouse gelatinase B 
and GADPH. 
This effect of RA was synergistic with that of LPS and 
CGP 41251, starting from 10 -11 M of RA. 
3.5. Effect of LPS, CGP 41251 and retinoic acid on RAW 
264.7 gelatinase B mRNA levels 
We have previously demonstrated [22] that an 18-h 
treatment with LPS was optimal in increasing the steady- 
state levels of gelatinase B mRNA in RAW 264.7 cells. 
Therefore, these cells were treated for 18 h with optimal 
doses of LPS, CGP 41251 and RA, either alone or in 
combination. Total RNA was extracted from the cells and 
hybridized with a probe specific for mouse gelatinase B
(Fig. 5). Densitometric analysis of the blots indicated a 
barely detectable increase of gelatinase B mRNA level in 
the CGP 41251-treated cells (15% of the LPS response) 
and no effect on RA-treated cells. However, the combina- 
tions CGP 41251 with LPS, RA with LPS and CGP 41251 
with RA gave 10-, 6- and 14-fold higher responses than 
LPS alone, respectively. Moreover, a combination of the 
three agents gave a 17-fold higher response, when com- 
pared to LPS alone. Zymographic analysis of the culture 
supernatants of the same specimens confirmed that CGP 
41251 and RA had comparable effects to that of LPS at the 
protein level (data not shown). 
4. Discussion 
Macrophages use matrix remodelling proteinases in the 
process of migration. In addition, these enzymes could 
possibly be at the biochemical basis of autoimmunity. The 
present study was undertaken to define regulatory path- 
ways in the modulation of gelatinase B activity by 
macrophages. 
Similar to many other cell types, macrophages can 
secrete two types of gelatinases: gelatinase A (_  70 kDa, 
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MMP-2) and gelatinase B (+90 kDa, MMP-9). Both 
enzymes are differently regulated in human and mouse 
primary macrophages and macrophagic cell lines. In this 
study, we focussed on the regulation of gelatinase B 
activity. All our experiments were done in serum-free 
medium to eliminate the gelatinolytic activity [5] and the 
possible modulatory factor(s) [26] contained in sera. A 
significant increase of gelatinase B production and a su- 
perinduction of this response induced by LPS and PMA 
have been observed in two different ypes of murine and 
human macrophages (RAW 264.7 and THP-1) treated with 
CGP 41251, a member of the staurosporine family of PKC 
inhibitors. This effect of CGP 41251 was not significant in 
human blood monocytes and rat peritoneal macrophages, 
although some induction was observed by densitometric 
analysis of the gels. Considering that human monocytes 
and rat peritoneal macrophages represent enriched, but not 
pure, preparations of cells, these ambiguous results are not 
surprising. For instance, the presence of contaminating 
cells in these preparations, or the use of macrophages at
different stages of differentiation, may explain this relative 
absence of stimulation when compared to RAW 264.7 and 
THP-1 cells. However, in no case did CGP 41251 inhibit 
gelatinase production of the four macrophage cell types 
studied, as it did for PMA-induced non-macrophagic tumor 
cell lines. The inhibitory effect of CGP 41251 on tumori- 
genic cell lines was expected since it has been previously 
described by our group [27] and others [28], using stau- 
rosporine. 
Therefore, considering that: (1) RAW 264.7 cells are 
inducible by LPS, the most studied macrophage stimulator; 
and (2) RAW 264.7 cells can accomplish many recognized 
macrophage functions [18-22], our results suggest that the 
RAW 264.7 cell line is representative of the macrophage, 
or at least of some subsets of this cell type, regarding the 
effect of CGP 41251 on the gelatinase B production. In 
RAW 264.7 cells, CGP 41251 acted in synergy with LPS 
for gelatinase B production, at both the mRNA and protein 
level, but concomitantly inhibited the LPS-induced NO 
production. Presently, we cannot rule out the possibility 
that the stimulation of gelatinase B production and the 
inhibition of NO production may be related to the toxicity 
of CGP 41251. However, the link between gelatinase B
and toxicity of CGP 41251 appears improbable since 
staurosporine, which is reportedly more toxic than CGP 
41251 [23], showed no stimulatory effect on the gelatinase 
B production in RAW 264.7 [22]. Gelatinase B production 
induced by LPS and CGP 41251 was also superinduced by 
RA. In fact, RA alone, which had no toxic effect on RAW 
264.7 cells (data not shown), appeared to be a gelatinase B 
inducer. Moreover, the triple combination of LPS with 
CGP 41251 and RA showed a higher esponse than any of 
these agents tested either alone or in double combination. 
Northern blots were performed at the optimal time of 
gelatinase B mRNA induction by LPS [22]. In the presence 
of LPS, two mRNA transcripts were detected by the mouse 
cDNA probe, confirming the results obtained by our group 
[14,22] and by others [29]. Our results (Fig. 5) revealed a
barely detectable ffect of CGP 41251, and no visible 
effect of RA on the steady-state l vels of gelatinase B
mRNA. A number of factors involved in the regulation of 
PMA- and LPS-induced responses, uch as Fos and IkB, 
could play a role in this regulation since these responses 
are known to possess negative regulatory activities which 
can be controlled through their phosphorylation state 
[30,31 ], Regarding the potentiating effects of LPS and RA, 
members of NF-kB (reviewed in Ref. [32]) and RA recep- 
tor (RAR) families (reviewed in Ref. [33]) represent good 
candidates for mediating the observed effects. Analysis of 
the known promoter egions of human [34] and murine 
[14] gelatinase B genes showed the presence of a NF-kB- 
binding element (GGAATTCCCC) in the 5' promoter 
region of both genes. No RA responsive lement (RARE; 
AGGTCAnnnAGGTCA) has been found in any of these 
two genes; however, as shown by Kitabayashi et al. [35], 
RA can bind to other sequences. In the case of the routine 
gelatinase B gene [14] the 5' promoter region contains five 
AGGTCT sites which differ by only one nucleotide from a 
consensus AGGTCA half-site potentially recognized by 
RAR and the thyroid receptor. RA may also act indirectly, 
through inhibition of a negative regulatory transcription 
factor. For instance, human RARce has been shown to 
possess a 'silencing' domain in its C-terminal part; in the 
absence of RA, this domain can inhibit gene transcription, 
a process which can be cell type-specifically neutralized 
by RA [36]. Several other mechanisms of negative regula- 
tion of transcription, such as competition between uclear 
factors or cross-talk between receptors and protooncopro- 
teins are also possible (reviewed in Ref. [37]), particularly 
if the presence of two AP1 sites in both the human and 
murine gelatinase B promoter egions is considered. Fi- 
nally, we cannot exclude a dual action of CGP 41251, RA 
and/or LPS on both positive and negative mechanisms of 
regulation [38]. 
The pretreatment of RAW 264.7 cells with different 
agents revealed that gelatinase B production induced by 
LPS and CGP 41251 shared common characteristics: (a) it 
was inhibited by calphostin C, one of the most selective 
PKC inhibitors (reviewed in Ref. [39]). Accordingly, this 
response appears to be PKC-dependent. Therefore, it seems 
that CGP 41251 would rather act as a PKC agonist, an 
observation which has been made by others, especially in 
the polymorphonuclear cell model [40-42]. CGP 41251 
may fail to inhibit the calcium-independent PKC isoforms 
while inhibiting the calcium-dependent isoforms [43,44]. If 
the ratio of calcium-dependent/calcium-independent PKC 
isoforms in macrophage is different from that of non-mac- 
rophagic tumor cells, the overall effect of CGP 41251 on 
gelatinase B production would be the opposite. On the 
other hand, CGP 41251 may also act on another enzyme, 
such as phospholipase D [42]. Finally, CGP 41251 may 
inhibit only the phosphorylative activities of PKC without 
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affecting its other potential regulatory activity, as proposed 
for the activation of phospholipase D by staurosporine 
[45]; (b) gelatinase B production was partially inhibited by 
okadaic acid, a phosphatase inhibitor; (c) it was also 
partially inhibited by genistein and herbimycin A, two 
tyrosine-specific protein kinase inhibitors; (d) gelatinase B 
production was not inhibited in the presence of KT 5720 
and KT 5823, two inhibitors of cAMP- and cGMP-depen- 
dent protein kinases; (e) finally, even though intracellular 
calcium had been modulated in a negative or a positive 
way (using EGTA and A23187, respectively), there was no 
significant change on gelatinase B production, indicating a
calcium-independent mechanism. Furthermore, using dexa- 
methasone, a major difference was demonstrated between 
LPS and CGP 41251: LPS-induced gelatinase B produc- 
tion was not affected, but CGP 41251-induced response 
was inhibited by more than 80%, suggesting that gluco- 
corticoid receptors are involved in the down-regulation f
CGP 41251-induced gelatinase B production. Transforma- 
tion of RAW 264.7 cells with different plasmids contain- 
ing one of these regulatory factor cDNAs under the control 
of a strong promoter, would certainly yield additional 
interesting results. 
In many cell types, including macrophages, MMP genes 
such as those coding for gelatinase B, collagenase and 
stromelysin, but not gelatinase A, respond in a similar 
fashion to LPS and PMA stimulation [12,16,27,46]. Fur- 
thermore, these genes contain cis-acting elements, such as 
AP1- and NF-kB-binding sites, in their promoter egion 
(reviewed in Ref. [6]). Until now, relatively few result 
have been reported with other MMPs regarding PKC 
inhibitors. Staurosporine was reported to inhibit stromelysin 
production induced by nerve growth factor in PCI2, a rat 
pheochromocytoma cell line [47]. However, a number of 
studies were performed on the inhibitory effect of RA and 
dexamethasone on different constructs containing the pro- 
moter region of collagenase and the CAT reporter gene 
[35,48]. Regarding elatinase B, staurosporine was shown 
to induce it in human neutrophils [40]. Recently, it was 
reported that staurosporine stimulated the expression of 
gelatinase B and collagenase in rat mucosal keratinocytes 
and that dexamethasone i hibited gelatinase B production 
induced by transforming rowth factor oz and epidermal 
growth factor, but not by PMA [49]. 
Our results raise interesting questions regarding the 
therapeutic use of PKC inhibitors and RA in cancer ther- 
apy and prevention trials, as well as in inflammatory 
diseases, particularly since a number of reports suggest 
that gelatinase B might play a role in metastasis develop- 
ment (reviewed in Refs. [6,7]) and in inflammatory pro- 
cesses [8]. In all nonmacrophagic tumor cell lines that we 
and others [27,50] have tested so far, gelatinase B produc- 
tion was always inhibited by PKC inhibitors such as 
calphostin C, staurosporine and CGP 41251. Because 
gelatinase B production of tumor-infiltrating macrophages 
would simultaneously be increased by these treatments, it 
would remain possible for 'metastasizing' tumor cells to 
use this enzyme to break the surrounding ECM [7,51]. Our 
results also suggest hat agents such as CGP 41251 and 
RA can inhibit LPS-inducible products possessing tumori- 
cidal and inflammatory properties, such as TNF-c~ and 
NO, while concomitantly stimulating the production of 
gelatinase B and, possibly, other molecules implicated in 
inflammatory diseases and cancer. Therefore, the search 
for substances that would inhibit or carefully balance the 
production of all these factors could potentially improve 
the benefits of such types of treatment. 
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